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Membrane and cytosol fractions from hepatocytes of both normal and streptozotocin-induced diabetic animals were probed with a panel of 
polyclonal anti-peptide antisera in order to identify protein kinase C (PKC) isoforms. Immunoreactive species were noted with antisera specific 
for ~ (-81 kDa), fl-ll ( -82 kDA), E (--95 kDa) and ~" (~ 79 kDa). In addition, a species migrating with an apparent size of -94  kDa was also 
detected in cytosol fractions using an antiserum specific for PKC-c~. Each of these species was specifically displaced when the PKC-isoform specific 
peptide was included in the immunodetection system. No immunoreactive species consistent with the presence of the fl-I, 7, ~ and 1/isoforms of 
protein kinase C was observed. Induction of diabetes using streptozotocin invoked selective alterations in the expression of PKC isoforms which 
were reversed upon insulin therapy. In the cytosol fraction, marked increases of ~ 3-fold occurred in levels of the fl-I1 isoform and the ~ 90 kDa 
(upper) form of PKC-~, with no apparent/little change in the levels of the - 81 kDa (lower) form of PKC-cc and those of PKC-~'. Diabetes induction 
also appeared to have elicited the translocation of PKC-fl-II and the -81 kDa (lower) form of PKC-c~ to the membrane fraction where 
immunoreactivity for these species was now apparent. The level of PKC-e, which was noted only in membrane fractions, was also increased upon 
induction of diabetes. It is suggested that the selective alterations inthe expression ofPKC isoforms occurring upon streptozotocin-induced diabetes 
may lead to altered cellular functioning and underly defects in inhibitory G-protein functioning and insulin action which characterise this animal 
model of diabetes. 
Protein kinase C: Isoform; Diabetes: Streptozotocin; I sulin; Liver; Hepatocyte; Phosphorylation 
1. INTRODUCTION 
Protein Kinase C (PKC) was first discovered in 1977 
as an undefined protein kinase which was activated by 
limited proteolysis with the neutral protease calpain [1]. 
Its ability to be activated by turnout-promoting phorbol 
esters and by diacyl glycerol (DAG), produced through 
receptor-stimulated phospholipid metabolism, has led 
to the realisation that this enzyme plays a major role in 
signal transduction events [1-4]. 
Molecular cloning and enzymological nalysis have 
now identified a number of structurally related protein 
kinase C isozymes which include the Ca2+-regulated spe- 
cies ~, ill, flII, 7, and those that lack such a regulatory 
domain, namely g, e, r/, ( and L-forms [5-8]. There is 
considerable interest in the possibility that individual 
isoforms may have distinct functional roles in the cell. 
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These may be reflected by differences in their degree of 
activation, target protein specificity, susceptibility oac- 
tivation by DAG species with different acyl chains, sen- 
sitivity to Ca 2+ and arachidonate and also regulation by 
phosphorylation [1,3,5,6,9,10]. There is also some data 
indicating the selective xpression of protein kinase C 
isoforms, with PKC-c~ apparently being expressed ubiq- 
uitously in mammalian cells, flII being found in most 
tissues and with other isoforms showing much more 
restricted cellular distributions [1,5,6,11,12]. That there 
are differences in the distribution between membrane 
and cytosol fractions of the various isoforms and that 
some species can undergo translocation as a result of 
ligand or phorbol ester challenge [14] again indicates 
that specific functions may be attributable to members 
of this enzyme family. 
There is now considerable vidence for the occur- 
rence of 'cross-talk' between different signalling path- 
ways [13,14]. This certainly occurs in hepatocytes, 
which provides a good example of the modulation of 
adenylyl cyclase and cyclic AMP metabolism by lipid 
signalling pathways exerting actions through PKC [13 
17]. The desensitization f glucagon's ability to stimu- 
late adenylyl cyclase takes the form of an uncoupling of 
the receptor from Gs which is mediated through the 
activation of protein kinase C and is presumed to result 
from the phosphorylation f the glucagon receptor [18]. 
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Such cAMP- independent  act ions o f  g lucagon appear  to 
be att r ibutable  to its abi l i ty to act ivate l ipid signal l ing 
pathways  leading to the product ion  o f  DAG [19-22], 
e levat ion o f  Ca 2+ levels and the act ivat ion o f  PKC 
[22,23]. The recent mo lecu la r  c loning o f  the g lucagon 
receptor  indicates that  a single receptor,  able to couple 
to more  than one signal l ing system, is responsib le for 
these act ions [24]. As well as this, act ivat ion o f  protein 
kinase C also causes the loss o f  ' tonic '  GTP-med ia ted  
inhib i t ion o f  adenyly l  cyclase th rough Gi [17]. This  ap- 
parent ly  physio logical  'crossta lk '  mechan ism appears,  
however,  to be inappropr ia te ly  act ivated in strepto-  
zotoc in - induced iabetes [25,26] where we have noted 
the loss o f  such ' ton ic '  GTP-e l i c i ted  inhib i t ion o f  ade- 
nylyl cyclase [25,26]. This appears  to be due in part  to 
the reduced express ion o f  the inhib i tory G-prote in  ~-Gi-  
2 but  also to the increased phosphory la t ion ,  th rough the 
act ion o f  PKC,  o f  ~-Gi-2 itself [18,26]. 
S t reptozotoc in - induced diabetes has recently been 
shown [27] to lead to increased levels o f  the f l - I I  i so form 
in the membrane ,  but  not  the cytosol  f ract ion,  o f  rat 
aor ta  and heart,  whilst not  affect ing the expression o f  
the ~ isoform. It is possible that abnormal i t ies  in PKC 
expression might  occur  in hepatocytes  f rom strepto- 
zotoc in - induced iabetes as reflecting the altered func- 
t ion ing o f  this enzyme act iv ity deduced f rom analyses 
done on Gi funct ion and phosphory la t ion  [25,26]. We 
here descr ibe the use o f  a panel  o f  sub-type specific 
ant isera to probe a l terat ions in the express ion and dis- 
t r ibut ion,  between membrane  and cytosol  compar t -  
ments,  o f  var ious prote in kinase C isoforms.  
2. MATERIALS  AND METHODS 
2.1. Materials 
Streptozotocin, 1 2-dioleoylglycerol, histone H1 (type IIIS), apro- 
tinin were from Sigma, Poole, Dorset, UK. Leupeptin was from Pep- 
tide Synthesis Inc., via Scientific Research Associates, London, UK. 
Phosphatidylserine was from Lipid Products, London, UK. Collage- 
nase and Diabur-Test 5000 was from Boehringer Mannheim Biochem- 
icals, UK. Dextrostix for blood glucose determination was from Ames 
Division, Miles Ltd., Slough, UK. [y-3-'P]ATE ECL detection kit and 
ECL-hyperpaper were from Amersham International, Amersham, 
Bucks, UK. Bradford reagent was from Bio-Rad. HRP-antirabbit 
antibody and donkey serum were from Scottish Antibody Production 
Unit, Scotland. Lentard MC porcine/bovine insulin was from Novo 
Laboratories Ltd., Basingstoke, UK. All other reagents were at least 
AnalaR grade, from Sigma, Boehringer Mannheim Biochemicats. 
The protein kinase C isozyme-specific antisera employed were as 
described previously by one of us [28]. These were raised using pep- 
tides corresponding tounique sequences within the different isozymes 
ct, flI, flII, y, e and (. Their specificity has been reported on previously 
[28]. Results were also confirmed using a new panel of antisera (prefix 
GUCSG-; results not shown). The antisera codes were for ~-PKC 
((C)-PQFVHPILQSAV, V5 domain) [28] and also antiserum 
GUCSG-1986ct (amino acids 317 329; VISPSEDRRQPSC); flII- 
PKC(fll-), with antiserum v5fll (C-SEFLKPEVKS) [28] and also 
antiserum GUCSG-1942flII (amino acids 660-673;C-SFVNSE- 
FLKPEVKS); flI-PKC(,82-), with antiserum v5f12 [28] (C- 
NPEFVINV) and also antiserum GUCSG-647flI (amino acids; 
C-RDKRDTSNFDKEFT); T-PKC, with antiserum v5), (C-PDAR- 
SPISPTPVPVM) [28] and also antiserum GUCSG-1726y (amino 
acids 306-318; C-NYPLELYERVRTG); e-PKC, with antiserum e 
(C-NQEEFKGFSYFGEDLMP) [29] and also antiserum GUCSG- 
637e (amino acids 721-737; C-NQEEFKGFSYFGEDLMP); (-PKC, 
with antiserum ~" [30] and also antiserum GUCSG- 1985~" (amino acids 
577-592; C-GFEYINPLLLSAEESV); and an antiserum against the 
C-terminal decepeptide of protein kinase C ¢~ (C-VNPKYEQFLE) 
called antiserum-d [31] and with antiserum r/ (C-QDE- 
FRNFSYVSPELQ) [32]. We also employed the MC5 monoclonal 
antibody which recognises the ct, fl-I1, fl-II and y forms of protein 
kinase C [33]. 
2.2. Induction of experimental diabetic" rats 
The induction of diabetes (single dose of streptozotocin, 80mg/kg 
body wt. in sodium citrate pH 4.5, i.p.) into male Sprague-Dawley rats 
(180 200 x g) with assessment ofglucose levels in urine and blood, was 
done as described before in detail by one of us [25]. In some instances 
the diabetic animals were subdivided into insulin-treated oruntreated 
group with, as before [25], insulin-treated animals received a daily 
subcutaneous injection of 10 I.U. of Lentard porcine insulin for 7 
days, beginning 4 days after streptozotocin administration. 
2.3. Preparation of hepatocytes 
Hepatocytes were prepared from fed male Sprague Dawley rats 
(200 250 x g) essentially as previously described by us [15,23], using 
a procedure based upon that of Berry and Friend [34], except that 0.75 
mM CaCI 2 was added to the collagenase-containing buffer. After 
isolation, the cells were washed twice in Hanks balanced salt solution 
and then resuspended in 10 vol. of Hanks buffer supplemented with 
1% (w/v) dialysed fatty acid free BSA. 50 ml of the resulted suspension 
was pre-incubated at 37°C (gassed with O2/CO 2, 19:1) for 30 min 
before any experimental manipulation. 
2.4. Preparation of hepatocyte extracts and whole liver extracts 
Hepatocytes were sedimented and further washed twice in 10 vol. 
of ice-cold PBS and resuspended in 10 ml of homogenisation buffer 
(20 mM Tris-HCl, 2 mM EDTA, 2 mM EGTA, 6 mM fl-mercapto- 
ethanol, 20/,tg/ml leupeptin, 4/~g/ml aprotinin, pH 7.4). All procedures 
were carried out at 4°C from this point unless otherwise stated. Cells 
were then lysed by either employing a very brief period of sonication 
on ice with a micro-probe attachment for three 10 s bursts on a Dawes 
sonicator at 80 W [23] or by using the gentle N2-pressurisation and 
homogenisation procedure developed by us previously [15]. The re- 
sulting homogenates (15 ml) were centrifuged at 1,500 x g at 4°C for 
10 min to remove unbroken cells. The pellets were discarded and the 
supernatant was centrifuged at 100,000 x ga~ at 4°C for 30 rain on a 
Beckman L-8 ultracentrifuge with a Ti60 rotor. The resultant superna- 
tant, referred as the cytosolic extract, was collected, aliquotted and 
stored at -80°C until use. The pellet was resuspended in 8 ml of 
homogenisation buffer containing 1% (v/v) Nonidet P-40 and left to 
extract for 30 min. The mixture was then centrifuged at 100,000 x g 
at 4°C for 30 min and the supernatant is referred as the membrane 
extract and was stored at -80°C. The protein concentration was 
determined by the method of Bradford [35] using dialysed fatty acid 
free BSA as standard. 
When cytosolic and membrane extracts were prepared from whole 
liver, the following procedure was used in order to minimize contam- 
ination with protein from blood and blood cells. Sprague Dawley rats 
were anesthetised byintraperitoneal injection of 0.3 ml Sagatal. When 
the animal was unconscious, 0.2 ml of heparin solution (1 mg/ml) was 
infused into the tail vein. The vena cava was cannulated and led to 
waste. The liver was perfused via the portal vein with ice-cold PBS, 
supplemented with 2 mM EGTA and 2 mM EDTA ('PEE' buffer), 
until the liver was clear of blood and attained ice-cold temperature. 
All procedures were carried out at 4°C from this point unless other- 
wise stated. The liver was excised into PEE buffer, cut into small pieces 
and rinsed with 20 ml homogenisation buffer. The tissue was resus- 
pended in 40 ml of homogenisation buffer and homogenised with 15 
strokes in a Dounce homogenizer. The resultant homogenate was 
treated as described above for hepatocyte homogenates. 
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2.5. Immunoblotting ofprotein kinase C isozymes 
Cytosolic extracts (200 ¢tg of protein) and membrane extracts (200 
¢tg of protein) were separated by SDS/PAGE (7.5% gels) after being 
solubilised and boiled in Laemmli buffer [36]. Western blotting was 
performed essentially asdescribed before by us (see e.g. [37]) using a 
2 h transfer time onto nitrocellulose paper in blotting buffer (0.005% 
SDS, 5 g/l Tris base and 14.4 g/l glycine). The blots were blocked with 
4% (w/v) skimmed milk, 2% (v/v) donkey serum in PBS, 0.05% NP-40 
and 20%-methanol f r 2 h, followed by an incubation with the desig- 
nated isozyme sp cific antiserum (appropriately diluted in 0.02% thim- 
erosal) overnight. The blots were rinsed four times for 15rain each 
with PBS/0.05% Nonidet P-40 and then probed with HRP-donkey 
anti-rabbit antiserum (1:250 in blocking solution) for 2 h,followed by 
four rinses in PBS/005% Nonidet P-40, each for 15 min. The blots were 
finally rinsed in PBS and immuno-detection wascarried out using an 
enhanced chemilluminescence kit from Amersham International (ECL 
kit). The procedure was carried out as described as per the manufac- 
turers instructions and immunoreactivity visualised using ECL-hyper- 
paper exposed for 2 30 rain. The images on hyperpaper were quanti- 
tated by densitometry on a Shimadzu CS-9000 scanning densitometer. 
In experiments where synthetic C-terminal peptides were used to 
compete with protein kinase C for binding to theisozyme-specific 
antisera, these (stock concentration of 1 mg/ml) were pre-mixed at a 
ratio of 1:1 with the antisera nd then incubated for 1 h before being 
diluted into the blocking solution. 
3. RESULTS AND DISCUSSION 
In hepatocytes of streptozotocin-induced diabetic 
rats [25,26] there is a loss of Gi function which appears 
to result from both a reduction in the expression of Gi-2 
and also its increased phosphorylation by protein ki- 
nase C. Treatment of a variety of different cell types 
with tumour promoting phorbol esters has been shown 
to lead to the loss of guanine nucleotide-elicited, G~- 
mediated inhibition of adenylate cyclase activity [13,37]. 
Similar observations of crippled G~ function have also 
been seen in cells challenged with ligands which stimu- 
late phospholipid metabolism or with DAG [13], sug- 
gesting that it is the activation of protein kinase C which 
provides the molecular basis of this phenomenon. In- 
deed, studies on hepatocytes [14,18,26,38], platelets [39 
41] and U973 cells [42] have indicated that the c~-subunit 
of G~-2 may provide a target for phosphorylation of 
Gi-2. And, certainly, in hepatocytes [14,18] the loss of 
guanine nucleotide-mediated inhibition of adenylate 
cyclase parallels the phosphorylation of ~-Gi-2. Consis- 
tent with such observations are those showing that 
treatment of either purified G~ [43] or membranes 
[18,25] with purified brain protein kinase C prepara- 
tions led to the phosphorylation of c~-G~-2. 
Such observations of loss of tonic GTP-elicited Gi 
function suggest hat there may be aberrations at the 
level of PKC in hepatocytes of streptozotocin-induced 
diabetic rats. In order to assess whether changes in ex- 
pression ensued as a result of the induction of diabetes, 
we utilised immunoblotting techniques to detect PKC 
in cytosol and membrane fractions from hepatocytes of 
normal rats, those made diabetic with streptozotocin 
and diabetic rats subjected to insulin therapy in order 
to normalise their hypoinsulinaemia nd hypergly- 
caemia. Initial experiments were done using the mono- 
clonal antibody MC5 to detect PKC. This antibody is 
non-selective as regards the major PKC isoforms [33] 
and was used here merely as a general indicator of 
changes in expression occurring in PKC levels. We have 
previously noted [23] that this antibody detects a single 
immunoreactive species of - 84 kDa in both the cytosol 
and membrane fraction of hepatocytes. In the present 
study we noted that diabetes induction elevated levels 
of detected PKC immunoreactivity around 2-fold 
(105 + 12% and 93 + 11% increase over control, respec- 
tively) in the cytosol and membrane fractions 
(means + S.D., n = 4 separate xperiments using differ- 
ent aminals; data not shown). 
In order, however, to attribute changes to specific 
PKC isoforms we used a previously characterised (see 
section 2) panel of polyclonal antisera specific for the 
o~, fl-I, fl-II, 7, ~, e, 11 and ( isoforms. Analysis of mem- 
brane and cytosol fractions from hepatocytes of both 
normal and streptozotocin-induced diabetic animals 
failed to identify immunoreactive species consistent 
with the presence of the fl-I, ?', ~ and r/isoforms of PKC 
(n = 5 separate xperiments using different cell prepara- 
tions). However, immunoreactive species were noted 
with antisera for c~, fl-II, e and ( which co-migrated with 
that detected in a purified brain PKC preparation 
(Fig. 1). 
Intriguingly, however, analysis of the cytosol fraction 
with antisera for PKC-c~ led us to observe an additional 
immunoreactive species which migrated more slowly, 
with an apparently higher molecular size of -90  kDa, 
compared to that of the 81 kDa species found in both 
membrane and cytosol fractions (Sections 1 and 2, Fig. 
1). Both these species which were detected with the anti- 
PKC-c~ antisera appeared to be authentic PKC-c~ enti- 
ties in that their detection was specifically ablated when 
the PKC-~ peptide was included in the immunodetec- 
tion (blotting) assay. The - 81 kDa species is of a sim- 
ilar size to that reported by others for PKC-0~ purified 
from brain (see e.g. Marais and Parker [28]), although 
that, in itself, is larger than the molecular size of 
76.8 kDa that can be predicted from the sequence de- 
duced from cDNA cloning [44]. It has been noted, how- 
ever, that PKC-~ and other isoforms are subject to 
posttransational modification which can lead to marked 
alterations in their apparent molecular size upon SDS- 
PAGE (see e.g. [10]) which may explain the apparent 
presence of multiple forms of protein kinase C-c~ seen 
here and by others previously [10]. 
We also observed marked differences in the distribu- 
tion of the various PKC isoforms between membrane 
and cytosol fractions. Thus the more slowly migrating 
form of PKC-c~ appeared only to occur in the cytosol 
fraction as did the majority of the -81  kDa form of 
PKC-~ (Section 1, Fig. 1; Table I). Similarly, the fl-II 
isoform was essentially only detected in the cytosol frac- 
tion (Sections 3 and 4, Fig. 1 : Table I), where it migrated 
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as a species of around 82 kDa. This size is similar to that 
observed for the purified isoform from brain (see e.g. 
[28]) but larger than the molecular size of -77  kDa 
predicted from the cDNA sequence [44]. 
In contrast o the location of the fl-II isoform, PKC-e 
was only detected in the membrane fraction (Sections 
4 and 5 of Fig. 1; Table I) where it was found as species 
o f -  95 kDa. This is of a similar size (--89 kDa) to that 
noted by Schaap et al. [29] for the brain enzyme ex- 
pressed in COS cells. 
PKC- (  was apparently equally distributed, as a - 79 
kDa species, between both membrane and cytosol frac- 
tions (Fig. 1). Its size compares with a value of ~ 80 kDa 
reported for the enzyme detected using immunoblotting 
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Fig. 1. Identification ofPKC isoforms in hepatocyte membrane and cytosol fractions. Membranes and cytosol fractions of hepatocytes from normal 
animals, streptozotocin-diabetic animals and insulin-treated streptozotocin diabetic animals were subjected to SDS-PAGE and subsequently 
immunoblotted with isoform-specific PKC antisera. The gels shown are typical of experiments done at least four times with cells made from different 
animals. In all sections the track labelled 'B' refers to a purified PKC preparation made from brain. Section 1 shows PKC-~ antiserum used to 
analyse membrane (MC, MD, MI) and cytosol (CC, CD, CI) fractions from normal (MC, CC), streptozotocin-diabetic (MD, CD) and insulin- 
treated streptozotocin diabetic (MI, CI) fractions. Note the co-migration of an immunoreactive species of - 84 kDa (lower arrow) in hepatocyte 
samples with that seen in a purified protein kinase C preparation from brain (B). A more slowly migrating species of -90  kDa (upper arrowed 
band) is also identifiable. In section II the use of a competing peptide (CP, BP) is shown, which specifically blocks interaction of the antiserum 
with PKC-~ species in brain (B) and both the --84 (lower arrow) and -90  kDa (upper arrow) species identifiable in hepatocyte cytosol (C) 
preparations. Sections 3 and 4 show the use of PKC-flII antiserum to analyse cytosol (CC, CD, CI) and membrane (MC, MD, M1) fractions from 
normal (MC, CC), streptozotocin-diabetic (MD, CD) and insulin-treated streptozotocin diabetic (MI, CI) fractions. The - 82 kDa species (arrowed) 
which co-migrates with that detected in a purified PKC preparation from brain (B) could be specifically displaced by the competing peptide (Section 
2). Section 5 shows the use of a PKC-E specific antiserum to analyse both membrane (MC, MD, MI) and cytosol (CC, CD, CI) fractions from 
normal (MC, CC), streptozotocin-diabetic (MD, CD) and insulin-treated streptozotocin diabetic (MI, CI) fractions. A - 95 kDa species is noted 
in both membrane fractions and the PKC brain (B) preparation which is displaced specifically by the appropriate competing peptide (arrowed). 
Section 6 shows data labelled as per section 5 but using anti-sera specific for PKC-(. In this instance immunoreactivity is observed in both cytosol 
and membrane preparations with an apparent size of ~ 79 kDa (arrowed). 
<---- 
techniques appl ied to a var iety of  cell l ines [30]. This 
value is, however, greater than that predicted ( -67  
kDa)  f rom the eDNA sequence [45]. 
Table I 
Distribution of PKC isoforms between membrane and cytosol com- 
partments of hepatocytes. Membrane and cytosol samples isolated 
from rat hepatocytes were analysed by SDS-PAGE with subsequent 
immunoblotting using PKC isoform-specific antisera s described in 
Section 2. Scanning densitometry of immunoreactive bands allowed 
for the estimation of comparative changes in the levels of PKC 
isoforms occurring upon induction of diabetes using streptozotocin 
and in insulin-treated diabetic animals. The '%-age change' indicates 
the percentage increase/decrease (+) in PKC isoform levels compared 
to that seen in the control animals (e.g. a 100% change is equivalent 
to a doubling or 2-fold change in the level). Errors are + S.D. for at 
least 4 separate experiments using cell preparations from different 
animals. The 'upper' and 'lower' species of PKC-c~ refer to the - 94 
kDa and --84 kDa species, respectively (see Fig. 1 Section 1). ~n.a.' 
is not applicable as no immunoreactive species was apparent even 
under conditions where the applied sample protein level was doubled. 
'dr' is detectable in the diabetic state but not in the control state and 
thus no meaningful relative change can be calculated. 'n.c.' is no 
change in levels (< 10% difference). *Significant t P < 0.005; **sig- 
nificant at P < 0.01; ***not significant, Students t-test. 
Isoform % Change in PKC isoform levels occurring upon induc- 
tion of diabetes 
Membrane Cytosol 
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20+9*** 5+ 11"** 
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The induct ion  of  diabetes using streptozotoc in had a 
pro found effect upon  the levels of  expression and the 
d is t r ibut ion of  PKC isoforms. Subject ing the diabetic 
an imals  to insul in  therapy, however, indicated that such 
changes were reversible (Fig. 1; Table I), which mil i tates 
against  the effect of  streptozotocin being a non-specif ic 
act ion of  the compound act ing on  hepatic tissue but,  
rather, suggests that such changes were due to the dia- 
betic cond i t ion  itself. For  PKC-c~, the induct ion  of  dia- 
betes now al lowed for the detect ion of  the 81 kDa spe- 
cies in the membrane  fract ion as well as eliciting a small  
increase in that found in the cytosol (Fig. 1 Section 1; 
Table I). Most  dramat ic ,  however, was the large in- 
crease ( -2 - fo ld )  in the amount  of  the 90 kDa species 
whose locat ion appeared exclusive to the cytosolic frac- 
t ion (Fig. 1 Section 1; Table I). Such data imply an 
overall  increase in the expression of  PKC-~,  in both  
membrane  and cytosol fractions, coupled with the 
t rans locat ion of  a por t ion  of  the - 81 kDa species to the 
membrane  fraction. 
St reptozotoc in- induced diabetes elicited a marked in- 
crease in the amount  of  cytosol ic PDC-f l I I .  This was 
also accompan ied  by our  abi l i ty to detect immunoreac -  
tive PKC- f l I I  in membranes  f rom the hepatocyte of  dia- 
betic rats, imply ing that t rans locat ion of  PKC- f l I I  f rom 
the cytosol had occurred (Fig. 1 Sections 3 and  4; 
Table I). 
The PKC-e  isoform seemed to be exclusively associ- 
ated with the membrane  fract ion where diabetes induc-  
t ion caused an increase in its level (Fig. 1 Section 5; 
Table I). Interestingly, however, we noted that in hepa- 
tocytes from diabetic rats subjected to insul in therapy 
then levels of  the PKC-e  isoform were actual ly de- 
creased to values which were below those found in the 
control ,  unt reated  an imals  (Fig. 1 Sect ion 5). 
In  contrast  to the marked,  reversible changes in the 
expression of  PKC-~,  -flII and  e, which were induced 
by diabetes, we failed to observe any change in the level 
of  expression of  PKC- (  found in either membrane  or 
cytosol fractions. Nei ther  did t reatment  of  the diabetic 
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animals with insulin alter the levels of this PKC isoform 
(Fig. 1 Section 6; Table I). 
The increase in the levels and altered distribution 
between membrane and cytosol compartments of cer- 
tain protein kinase C isoforms may thus provide an 
explanation for the aberrant increase in the level of 
protein kinase C-mediated phosphorylation of Gi-2 seen 
in the hepatocytes of streptozotocin-induced diabetic 
rats [26]. As G~-2 is found to be partly phosphorylated 
under resting (basal) conditions in hepatocytes from 
normal animals [14,26,38] then it is possible that by 
merely effecting an increase in the amount of the PKC 
isoform responsible for phosphorylating this G-protein, 
then such an action could lead to an increase in the level 
of phosphorylation of Gi-2. The trigger influencing al- 
terations in PKC expression remains to be identified. 
However, elevated levels of both glucagon and vaso- 
pressin characterise streptozotocin-diabetic rats [46], 
both of which serve to increase hepatocyte DAG levels 
and can activate both membrane and cytosolic protein 
kinase C activity [23]. Thus such conditions of chronic 
stimulation may of themselves lead to alterations in 
PKC expression and intracellular distribution. 
Undoubtedly such changes in PKC expression are 
likely to have widespread effects, some of which may in 
themselves affect the action of insulin on target tissues. 
For the insulin receptor itself is known to provide a 
substrate for this enzyme [47-50] with such modifica- 
tions being implicated as attenuating at least certain of 
the functions of the receptor and thus exerting a selec- 
tive effect on its different signalling actions (Houslay 
[48]). It may be then that aberrant expression of specific 
PKC isoforms can alter cell signalling pathways leading 
to (selective) hormone resistant states. Such a reversible 
phenomenon may underly facets of insulin-resistance 
seen not only in streptozotocin-induced diabetes but in 
human type-I and type-II diabetes, prompting isoform- 
specific analyses of protein kinase C expression and 
distribution in such conditions. 
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